MET Forensic analysis

Trading Setup & Entry Strategy

MetLife (MET) currently trades at $81.07, sitting just below its Bollinger Band upper bound ($81.55) with a 14-day RSI of 64.94. Momentum is clearly bullish following a positive 5-day/10-day SMA crossover and a price position 8.62% above the 50-day SMA. However, the MACD histogram is at -0.0016, signaling potential exhaustion of the current rally.

• >Entry Strategy: Do not chase the current strength. Wait for a short-term mean reversion.
• >Entry Zone: $79.30 - $79.90 (10-day SMA confluence).
• >Scaling: Enter 40% at $79.80; add 30% at $78.50 (retest of support); add final 30% at $77.50 (200-day SMA).
• >Stop Loss: $76.20 (Hard stop below the Bollinger Lower Band and 200-day SMA).
• >Take Profit: $83.50 (Initial resistance) and $85.00 (Extension target).
• >Risk/Reward: ~1:2.4.

Executive Summary

MetLife shows strong technical momentum, consistently trading above its 50-day SMA ($74.63) and 200-day SMA ($77.52). Financials remain stable, with Q1 2026 adjusted earnings of $1.63B, up from $1.41B in Q1 2025. While the Widowmaker rule suggests caution given the RSI nearing overbought territory, the fundamental health and technical uptrend justify a BULLISH stance on pullbacks.

Recent Material Events (8-K Analysis)

• >Feb 2026: Issued $1.00B of 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2056, enhancing capital flexibility.
• >Strategic Reorganization: Continued integration post-Q4 2025 restructure, specifically highlighting MetLife Investment Management (MIM) as a distinct reportable segment to capture growth in institutional asset management.

Insider Trading Activity

• >No significant insider selling or buying reported on Form 4 in the immediate trailing 30 days. Current share buyback program remains active, with $1.32B remaining under the April 2025 authorization.

Financial Health & Forensics

• >Revenue Quality: Strong. Net Investment Income rose to $5.36B (vs $4.89B YoY).
• [WARN]Red Flags: Accumulated Other Comprehensive Income (AOCI) stands at ($19.23B), a significant headwind, though largely a result of interest rate dynamics on the bond portfolio rather than credit quality deterioration.
• >Liquidity: Cash and cash equivalents of $22.69B provide a robust cushion for operational requirements.

Valuation & Technical Reconciliation

• >Technical Bias: The stock is currently in an uptrend (Bullish_Crossing). The disconnect between the flat MACD and rising price/RSI suggests a pause in momentum is imminent.
• >Reconciliation: Fundamentals (earnings growth, solid ROE-supportive capital allocation) align with technicals. However, the price is extended relative to the 10-day SMA. A pullback is required to achieve the desired risk-asymmetry.

Short-Term Trading Strategy (2-5 Days)

• >Timeframe: Swing Trade (2–5 Days).
• >Position Sizing: 3% of total portfolio.
• >Max Hold: 7 days. If the stock does not break $82.00 by then, the momentum trap is likely, and a neutral stance is advised.

One-Liner Thesis: A fundamentally sound, well-capitalized insurer experiencing a technical breakout, currently overextended, favoring a buy-the-dip approach on a 10-day SMA retest.